Thank you, Deepak. Now let’s review the financial results for our first quarter in greater detail. Our first quarter revenues were down 4% compared with that of the prior year Q1 or approximately 2% on a constant currency basis given the strength of the dollar. Fiscal first quarter Security division revenues were down 3%, largely due to the unfavorable FX impact. The Security division book-to-bill as Deepak mentioned was approximately 1.4, positioning the division well going forward and we anticipate significant sales growth commencing this quarter. Opto sales increased 2% year-over-year on the growth of intercompany sales to support anticipated upcoming security sales, while Opto third-party sales were consistent with third-party sales in the prior year quarter. Opto bookings were again solid, leading to a record Opto backlog, but supply chain constraints have led to delays in production and shipments of certain orders. The Healthcare division reported a 14% reduction in year-over-year revenues in part due to a tougher year-over-year comp, given the prior year demand during the COVID Delta variant surge. The Q1 gross margin was 32.6%, about 2.9% below that of the prior year. This change was primarily driven by the lower sales in the Healthcare division, which carries the highest gross margin of our three divisions, higher Opto sales as a percentage of total sales, as this division tends to carry the lowest gross margin of the three divisions, and a less favorable mix in the Security division sales with increases in certain component and freight costs adversely impacting each division’s gross margin. Our gross margin, in general, will fluctuate from period-to-period based on revenue mix and volume, inflation, impacts to the supply chain, among other factors. Moving to operating expenses, we continue to work diligently across each of our divisions to improve efficiencies and prudently manage our SG&A cost structure. Our Q1 results again demonstrated the success of these efforts. Q1 SG&A expenses were $53.4 million or 19.9% of sales, compared to $57.3 million or 20.5% of sales in the prior year Q1. While foreign exchange was a headwind to the topline revenues, it did have a beneficial impact on our operating expenses. Research and development expenses in Q1 of fiscal 2023 were $14.5 million, relatively consistent with that of the prior year. We continue to dedicate considerable resources to R&D, particularly in Security and Healthcare, as we remain focused on innovative product development, which we view as vital to the long-term success of our businesses. In Q1 of fiscal 2023, we recorded $1.2 million of restructuring and other charges, compared to $2.5 million of such charges in Q1 of the prior fiscal year. Moving to interest and taxes. Net interest and other expense in Q1 of 2023 increased to $3.4 million from $2 million in the same prior year period, primarily due to rising interest rates and the maturity of our 1.25% convertible notes on September 1st, which were at a lower rate than our current borrowings. We executed an interest rate swap during Q1 to fix a portion of our floating rate debt. On the tax side, our reported effective tax rate under GAAP was 24.4% in Q1 of fiscal 2023, compared to 15.9% in Q1 of fiscal 2022. In Q1 of fiscal 2023, we recognized a discrete tax benefit of $0.1 million, as compared to a discrete tax benefit of $2.1 million in Q1 last year. Excluding the impact of discrete tax items, our normalized effective tax rate in Q1 of 2023 was 25.1%, compared to an effective normalized rate of 25.4% in Q1 of fiscal 2022. I will now turn to a discussion of our non-GAAP adjusted operating margin. Overall, our adjusted operating margin in Q1 of fiscal 2023 decreased to 8.7% from 10.9% in the same prior year period. This was primarily driven by the reduction in revenues and gross margin previously described. We were pleased with the increase in the adjusted operating margin in our Opto division, which expanded 12.7% in the first quarter of fiscal 2023 from 11.4% in the prior fiscal year first quarter due to a more favorable product mix and implementation of certain efficiency improvement initiatives. The adjusted operating margin in the Security division decreased to 12.8% in Q1 from 16.2% in the prior year first quarter on lower revenue with reduced gross margin on a less favorable product mix. We expect nice sequential improvement in this division in Q2 on stronger revenues and a more favorable revenue mix. With lower revenues and a less favorable revenue mix, the adjusted operating margin of our Healthcare division decreased to 4.9% from 12.1% in the prior year quarter. We are forecasting this division to show significant improvement over Q1 as early as this quarter. Moving to cash flow, cash flow provided by operations were $17 -- was $17 million in Q1 of fiscal 2023 compared to cash used in operations of $11 million in the same prior year quarter. The increase was driven by working capital improvements. CapEx in the fiscal first quarter was $3.2 million, while depreciation and amortization in Q1 was $9.5 million. We continue to be active in our stock buyback program in Q1 of fiscal 2023, during which we spent $17.3 million to repurchase about 208,000 shares. Our Board increased the buyback authorization in September, and as of quarter end, approximately 1.9 million shares were available to repurchase under the program. Our balance sheet is solid, with net leverage of 1.6 and significant capacity for acquisitions and additional stock buybacks. We retired the convertible notes in September utilizing a combination of our revolver and term loan, which we had put in place in December 2021, primarily for this purpose leaving plenty of liquidity. Aside from about $7 million of annual required principal payments under the term loan, the bulk of our debt matures in fiscal 2027. And finally, turning to guidance, we are reiterating our previous revenues and non-GAAP adjusted earnings per share guidance. This implies revenue growth in the range of 7% to 11% and adjusted EPS growth of 17% to 22% over the remaining nine months of fiscal 2023. The non-GAAP diluted EPS range excludes potential impairment restructuring and other charges, amortization of acquired intangible assets and non-cash interest expense, and their associated tax effects, as well as discrete tax and other non-recurring items. We currently believe this revenue and non-GAAP earnings guidance reflect reasonable estimates. The actual impact on the company’s financial results of the COVID pandemic, disruptions and increased costs in the supply chain and rising inflation and interest rates is difficult to predict and could vary significantly from the anticipated impact currently reflected in our estimates and guidance. Actual revenues and non-GAAP earnings per diluted share could also vary from the anticipated ranges due to other risks and uncertainties discussed in our SEC filings. We continue to remain focused on the growth of our businesses and continued proactive management of our cost structure. We believe our efforts in these areas will enable OSI to continue providing innovative products and solutions. We look forward to continuing to navigate through the current dynamic and challenging environment, while gaining traction in key strategic growth areas and positioning the company to capitalize on improving end markets such as aviation. We would like to take this opportunity to thank the global OSI Systems team for its continued dedication in supporting our customers and our partners. And at this time, we would like to open the call to questions.